RT Journal Article
SR Electronic
T1 Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.06.10.145144
DO 10.1101/2020.06.10.145144
A1 Kyle Rosenke
A1 Michael A. Jarvis
A1 Friederike Feldmann
A1 Benjamin Schwarz
A1 Atsushi Okumura
A1 Jamie Lovaglio
A1 Greg Saturday
A1 Patrick W. Hanley
A1 Kimberly Meade-White
A1 Brandi N. Williamson
A1 Frederick Hansen
A1 Lizette Perez-Perez
A1 Shanna Leventhal
A1 Tsing-Lee Tang-Huau
A1 Martha Nason
A1 Julie Callison
A1 Elaine Haddock
A1 Dana Scott
A1 Graham Sewell
A1 Catharine M. Bosio
A1 David Hawman
A1 Emmie de Wit
A1 Heinz Feldmann
YR 2020
UL http://biorxiv.org/content/early/2020/06/11/2020.06.10.145144.abstract
AB We remain largely without effective prophylactic/therapeutic interventions for COVID-19. Although many human clinical trials are ongoing, there remains a deficiency of supportive preclinical drug efficacy studies. Here we assessed the prophylactic/therapeutic efficacy of hydroxychloroquine (HCQ), a drug of interest for COVID-19 management, in two animal models. When used for prophylaxis or treatment neither the standard human malaria dose (6.5 mg/kg) nor a high dose (50 mg/kg) of HCQ had any beneficial effect on clinical disease or SARS-CoV-2 kinetics (replication/shedding) in the Syrian hamster disease model. Similarly, HCQ prophylaxis/treatment (6.5 mg/kg) did not significantly benefit clinical outcome nor reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model. In conclusion, our preclinical animal studies do not support the use of HCQ in prophylaxis/treatment of COVID-19.One Sentence Summary Hydroxychloroquine prophylaxis/treatment showed no beneficial effect in SARS-CoV-2 hamster and macaque disease models.Competing Interest StatementThe authors have declared no competing interest.